161 related articles for article (PubMed ID: 29359239)
1. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
Breitkreutz I; Podar K; Figueroa-Vazquez V; Wilhelm S; Hayden PJ; Anderson KC; Raab MS
Ann Hematol; 2018 May; 97(5):839-849. PubMed ID: 29359239
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
Huynh H; Ong R; Zopf D
J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
[TBL] [Abstract][Full Text] [Related]
4. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
[TBL] [Abstract][Full Text] [Related]
6. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.
Subramonian D; Phanhthilath N; Rinehardt H; Flynn S; Huo Y; Zhang J; Messer K; Mo Q; Huang S; Lesperance J; Zage PE
Br J Cancer; 2020 Aug; 123(4):568-579. PubMed ID: 32457362
[TBL] [Abstract][Full Text] [Related]
9. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.
Okawa Y; Hideshima T; Steed P; Vallet S; Hall S; Huang K; Rice J; Barabasz A; Foley B; Ikeda H; Raje N; Kiziltepe T; Yasui H; Enatsu S; Anderson KC
Blood; 2009 Jan; 113(4):846-55. PubMed ID: 18948577
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib for cancer.
Strumberg D; Schultheis B
Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
[TBL] [Abstract][Full Text] [Related]
11. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
12. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
[TBL] [Abstract][Full Text] [Related]
15. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
16. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
18. Fucoidan inhibits angiogenesis induced by multiple myeloma cells.
Liu F; Luo G; Xiao Q; Chen L; Luo X; Lv J; Chen L
Oncol Rep; 2016 Oct; 36(4):1963-72. PubMed ID: 27498597
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.
Zopf D; Fichtner I; Bhargava A; Steinke W; Thierauch KH; Diefenbach K; Wilhelm S; Hafner FT; Gerisch M
Cancer Med; 2016 Nov; 5(11):3176-3185. PubMed ID: 27734608
[TBL] [Abstract][Full Text] [Related]
20. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]